IP Library Granted Patent US 9,675,662
Granted Patent B2
US 9,675,662 · App. 13/309,651 · Granted Jun 13, 2017

Compositions for inhibition of RNA polymerase I and methods of production and use thereof

Inventor: Lawrence Rothblum (Oklahoma City, OK)
Assignee: The Board of Regents of the University of Oklahoma
A61K38/1709C12N9/1247C07K2319/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,675,662
App. No.
13/309,651
Granted
Jun 13, 2017
Kind
B2
Abstract

Compositions for inhibition of RNA Polymerase I include peptides of Rpa43. Methods of production and use thereof are also disclosed.

Claims (59)

1. A method of inhibiting interaction of Rrn3 and Rpa43 in a cell, said method comprising at least one step selected from the group consisting of:

(a) administering to said cell a composition comprising an isolated peptide fragment and an element attached thereto, the element comprising a tag containing a protein transduction domain attached to the N-terminus of the peptide fragment, wherein the protein transduction domain enables the composition to transduce across the membrane of the cell, wherein the composition enters a nucleolus of the cell and inhibits interaction of Rrn3 and Rpa43 within the nucleolus of the cell; and

(b) introducing into a cell a recombinant vector comprising a nucleic acid sequence encoding a peptide fragment and an element attached thereto, the element comprising a tag containing a protein transduction domain attached to the N-terminus of the peptide fragment, wherein the peptide fragment is expressed within the cell and inhibits interaction of Rrn3 and Rpa43 within a nucleolus of the cell; and

wherein each of the isolated peptide fragment of (a) and the peptide fragment encoded by the nucleic acid sequence of (b) is 22-27 amino acids in length and comprises the sequence of:

(i) SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3;

(ii) X 1 X 2 X 3 X 4 X 5 X 6 H 7 X 8 G 9 X 10 L 11 X 12 H 13 G 14 X 15 X 16 N 17 A 18 S 19 X 20 P 21 K 22 (SEQ ID NO:4), wherein X 1 is N, F, or K; X 2 is K, R, L, or I; X 3 is V, Q, L, or M; X 4 is S, G, or A; X 5 is S, P, A, V, or T; X 6 is S or T; X 8 is I or V; X 10 is L or C, X 12 is V or I; X 15 is C, A, I, or T; X 16 is F or I; X 20 is I or V;

(iii) amino acids 6-27 of SEQ ID NO:179;

(iv) amino acids 4-25 of SEQ ID NO:180;

(v) amino acids 4-25 of SEQ ID NO:181;

(vi) amino acids 4-25 of SEQ ID NO:182;

(vii) amino acids 4-25 of SEQ ID NO:183;

(viii) amino acids 3-24 of SEQ ID NO:184;

(ix) amino acids 3-24 of SEQ ID NO:185;

(x) amino acids 4-25 of SEQ ID NO:186; or

(xi) amino acids 5-26 of SEQ ID NO:187.

2. The method of claim 1 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of rDNA transcription.

3. The method of claim 1 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of synthesis of 45S pre-ribosomal RNA.

4. The method of claim 1 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of cell growth.

5. The method of claim 1 , wherein the tag is a TAT peptide.

6. The method of claim 1 , wherein the isolated peptide further comprises a fluorescent tag.

7. The method of claim 1 , wherein the composition further comprises a targeting moiety.

8. A method of inhibiting interaction of Rrn3 and Rpa43 in a cell, the method comprising the step of:

administering to said cell a composition comprising an isolated peptide fragment and an element attached thereto, the element comprising a tag containing a protein transduction domain attached to the N-terminus of the peptide fragment, wherein the protein transduction domain enables the composition to transduce across the membrane of the cell, and wherein the isolated peptide fragment is 22-27 amino acids in length and comprises the sequence of:

(i) SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3;

(ii) X 1 X 2 X 3 X 4 X 5 X 6 H 7 X 8 G 9 X 10 L 11 X 12 H 13 G 14 X 15 X 16 N 17 A 18 S 19 X 20 P 21 K 22 (SEQ ID NO:4), wherein X 1 is N, F, or K; X 2 is K, R, L, or I; X 3 is V, Q, L, or M; X 4 is S, G, or A; X 5 is S, P, A, V, or T; X 6 is S or T; X 8 is I or V; X 10 is L or C; X 12 is V or I; X 15 is C, A, I, or T; X 16 is F or I; X 20 is I or V;

(iii) amino acids 6-27 of SEQ ID NO:179;

(iv) amino acids 4-25 of SEQ ID NO:180;

(v) amino acids 4-25 of SEQ ID NO:181;

(vi) amino acids 4-25 of SEQ ID NO:182;

(vii) amino acids 4-25 of SEQ ID NO:183;

(viii) amino acids 3-24 of SEQ ID NO:184;

(ix) amino acids 3-24 of SEQ ID NO:185;

(x) amino acids 4-25 of SEQ ID NO:186; or

(xi) amino acids 5-26 of SEQ ID NO:187; and

wherein the composition enters a nucleolus of the cell and inhibits interaction of Rrn3 and Rpa43 within the nucleolus of the cell.

9. The method of claim 8 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of rDNA transcription.

10. The method of claim 8 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of synthesis of 45S pre-ribosomal RNA.

11. The method of claim 8 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of cell growth.

12. A method of inhibiting interaction of Rrn3 and Rpa43 in a cell, the method comprising the steps of:

(a) introducing into said cell a recombinant vector comprising a nucleic acid sequence encoding an isolated peptide fragment and an element attached thereto, the element comprising a tag containing a protein transduction domain attached to the N-terminus of the peptide fragment, wherein the isolated peptide fragment is 22-27 amino acids in length and comprises the sequence of:

(i) SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3;

(ii) X 1 X 2 X 3 X 4 X 5 X 6 H 7 X 8 G 9 X 10 L 11 X 12 H 13 G 14 X 15 X 16 N 17 A 18 S 19 X 20 P 21 K 22 (SEQ ID NO:4), wherein X 1 is N, F, or K; X 2 is K, R, L, or I; X 3 is V, Q, L, or M; X 4 is S, G, or A; X 5 is S, P, A, V, or T; X 6 is S or T; X 8 is I or V; X 10 is L or C; X 12 is V or I; X 15 is C, A, I, or T; X 16 is F or I; X 20 is I or V;

(iii) amino acids 6-27 of SEQ ID NO:179;

(iv) amino acids 4-25 of SEQ ID NO:180;

(v) amino acids 4-25 of SEQ ID NO:181;

(vi) amino acids 4-25 of SEQ ID NO:182;

(vii) amino acids 4-25 of SEQ ID NO:183;

(viii) amino acids 3-24 of SEQ ID NO:184;

(ix) amino acids 3-24 of SEQ ID NO:185;

(x) amino acids 4-25 of SEQ ID NO:186; or

(xi) amino acids 5-26 of SEQ ID NO:187; and

(b) culturing the cell under conditions that allow for expression of the peptide fragment, wherein the peptide fragment is produced within the cell and inhibits interaction of Rrn3 and Rpa43 within the nucleolus of the cell.

13. The method of claim 12 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of rDNA transcription.

14. The method of claim 12 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of synthesis of 45S pre-ribosomal RNA.

15. The method of claim 12 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in the inhibition of cell growth.

16. The method of claim 1 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in cell death.

17. The method of claim 8 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in cell death.

18. The method of claim 8 , wherein the isolated peptide further comprises a fluorescent tag.

19. The method of claim 12 , wherein the inhibition of interaction of Rrn3 and Rpa43 results in cell death.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 20, 2013
From: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030452/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2011
From: ROTHBLUM, LAWRENCE I.
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
Reel/Frame 027360/0369 →
Continuity (1)
Related Publication 20130143318A1 · Jun 6, 2013